Alkem Laboratories Launches Generic Empagliflozin as "Empanorm"

Alkem Laboratories has launched generic Empagliflozin and its combinations in India under the brand name "Empanorm," priced significantly lower than innovator products. This move follows the expiry of Boehringer Ingelheim's patent on March 11, allowing domestic companies like Alkem, Mankind Pharma, and Torrent to offer affordable alternatives. Empagliflozin is crucial for treating diabetes, heart failure, and chronic kidney disease. Alkem's Empanorm will enhance accessibility and affordability for millions of patients, transforming India's diabetes care landscape.

 

Source: NSE, BSE, Times of India